Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies

NCT00202917 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT00202917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00202917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2010
Enrollment
61 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies